Suppr超能文献

一种Nutlin的解构:剖析一种强效蛋白质-蛋白质相互作用抑制剂的结合决定因素。

Deconstruction of a nutlin: dissecting the binding determinants of a potent protein-protein interaction inhibitor.

作者信息

Fry David C, Wartchow Charles, Graves Bradford, Janson Cheryl, Lukacs Christine, Kammlott Ursula, Belunis Charles, Palme Stefan, Klein Christian, Vu Binh

机构信息

Roche Research Center , 340 Kingsland Street, Nutley, New Jersey 07110, United States.

Roche Diagnostics GmbH , Nonnenwald 2, Penzberg 82377, Germany.

出版信息

ACS Med Chem Lett. 2013 May 24;4(7):660-5. doi: 10.1021/ml400062c. eCollection 2013 Jul 11.

Abstract

Protein-protein interaction (PPI) systems represent a rich potential source of targets for drug discovery, but historically have proven to be difficult, particularly in the lead identification stage. Application of the fragment-based approach may help toward success with this target class. To provide an example toward understanding the potential issues associated with such an application, we have deconstructed one of the best established protein-protein inhibitors, the Nutlin series that inhibits the interaction between MDM2 and p53, into fragments, and surveyed the resulting binding properties using heteronuclear single quantum coherence nuclear magnetic resonance (HSQC NMR), surface plasmon resonance (SPR), and X-ray crystallography. We report the relative contributions toward binding affinity for each of the key substituents of the Nutlin molecule and show that this series could hypothetically have been discovered via a fragment approach. We find that the smallest fragment of Nutlin that retains binding accesses two subpockets of MDM2 and has a molecular weight at the high end of the range that normally defines fragments.

摘要

蛋白质-蛋白质相互作用(PPI)系统是药物发现中丰富的潜在靶点来源,但从历史上看,已证明其具有挑战性,尤其是在先导化合物识别阶段。基于片段的方法的应用可能有助于在这类靶点上取得成功。为了提供一个例子来理解与这种应用相关的潜在问题,我们将已确立的最佳蛋白质-蛋白质抑制剂之一、抑制MDM2和p53之间相互作用的Nutlin系列分解为片段,并使用异核单量子相干核磁共振(HSQC NMR)、表面等离子体共振(SPR)和X射线晶体学研究了所得的结合特性。我们报告了Nutlin分子每个关键取代基对结合亲和力的相对贡献,并表明该系列理论上可以通过片段方法发现。我们发现,保留结合能力的Nutlin最小片段可进入MDM2的两个亚口袋,其分子量处于通常定义片段的范围的高端。

相似文献

1
Deconstruction of a nutlin: dissecting the binding determinants of a potent protein-protein interaction inhibitor.
ACS Med Chem Lett. 2013 May 24;4(7):660-5. doi: 10.1021/ml400062c. eCollection 2013 Jul 11.
2
On the interaction mechanisms of a p53 peptide and nutlin with the MDM2 and MDMX proteins: a Brownian dynamics study.
Cell Cycle. 2013 Feb 1;12(3):394-404. doi: 10.4161/cc.23511. Epub 2013 Jan 16.
3
On the origin of the stereoselective affinity of Nutlin-3 geometrical isomers for the MDM2 protein.
Cell Cycle. 2013 Dec 15;12(24):3727-35. doi: 10.4161/cc.27273. Epub 2013 Nov 21.
6
Structure of a stapled peptide antagonist bound to nutlin-resistant Mdm2.
PLoS One. 2014 Aug 12;9(8):e104914. doi: 10.1371/journal.pone.0104914. eCollection 2014.
7
Nutlin-3a-aa: Improving the Bioactivity of a p53/MDM2 Interaction Inhibitor by Introducing a Solvent-Exposed Methylene Group.
Chembiochem. 2023 Mar 14;24(6):e202300006. doi: 10.1002/cbic.202300006. Epub 2023 Feb 16.
8
NMR structure of a complex between MDM2 and a small molecule inhibitor.
J Biomol NMR. 2004 Oct;30(2):163-73. doi: 10.1023/B:JNMR.0000048856.84603.9b.

引用本文的文献

1
A Perspective on the Strategic Application of Deconstruction-Reconstruction in Drug Discovery.
J Med Chem. 2025 Jun 12;68(11):10520-10539. doi: 10.1021/acs.jmedchem.5c00036. Epub 2025 May 5.
2
ChemoDOTS: a web server to design chemistry-driven focused libraries.
Nucleic Acids Res. 2024 Jul 5;52(W1):W461-W468. doi: 10.1093/nar/gkae326.
3
Translating Senotherapeutic Interventions into the Clinic with Emerging Proteomic Technologies.
Biology (Basel). 2023 Oct 2;12(10):1301. doi: 10.3390/biology12101301.
4
Conformation-dependent ligand hot spots in the spliceosomal RNA helicase BRR2.
Acta Crystallogr D Struct Biol. 2023 Apr 1;79(Pt 4):304-317. doi: 10.1107/S2059798323001778. Epub 2023 Apr 28.
5
E3 Ligases Meet Their Match: Fragment-Based Approaches to Discover New E3 Ligands and to Unravel E3 Biology.
J Med Chem. 2023 Mar 9;66(5):3173-3194. doi: 10.1021/acs.jmedchem.2c01882. Epub 2023 Feb 23.
6
8
Query-guided protein-protein interaction inhibitor discovery.
Chem Sci. 2021 Mar 2;12(13):4753-4762. doi: 10.1039/d1sc00023c.
9
NMR as a "Gold Standard" Method in Drug Design and Discovery.
Molecules. 2020 Oct 9;25(20):4597. doi: 10.3390/molecules25204597.
10
Activity-Directed Synthesis of Inhibitors of the p53/hDM2 Protein-Protein Interaction.
Chemistry. 2020 Aug 21;26(47):10682-10689. doi: 10.1002/chem.202002153. Epub 2020 Aug 4.

本文引用的文献

1
Discovery of RG7112: A Small-Molecule MDM2 Inhibitor in Clinical Development.
ACS Med Chem Lett. 2013 Apr 2;4(5):466-9. doi: 10.1021/ml4000657. eCollection 2013 May 9.
2
Ligand efficiency as a guide in fragment hit selection and optimization.
Drug Discov Today Technol. 2010 Autumn;7(3):e147-202. doi: 10.1016/j.ddtec.2010.11.003.
3
Using chemical shift perturbation to characterise ligand binding.
Prog Nucl Magn Reson Spectrosc. 2013 Aug;73:1-16. doi: 10.1016/j.pnmrs.2013.02.001. Epub 2013 Mar 21.
4
MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models.
Cancer Res. 2013 Apr 15;73(8):2587-97. doi: 10.1158/0008-5472.CAN-12-2807. Epub 2013 Feb 11.
6
Fragment-based approaches in drug discovery and chemical biology.
Biochemistry. 2012 Jun 26;51(25):4990-5003. doi: 10.1021/bi3005126. Epub 2012 Jun 14.
7
Using fragment-based technologies to target protein-protein interactions.
Curr Pharm Des. 2012;18(30):4685-96. doi: 10.2174/138161212802651689.
8
The rise of fragment-based drug discovery.
Nat Chem. 2009 Jun;1(3):187-92. doi: 10.1038/nchem.217.
9
Fragment-based deconstruction of Bcl-xL inhibitors.
J Med Chem. 2010 Mar 25;53(6):2577-88. doi: 10.1021/jm100009z.
10
Rationalizing the chemical space of protein-protein interaction inhibitors.
Drug Discov Today. 2010 Mar;15(5-6):220-9. doi: 10.1016/j.drudis.2009.11.007. Epub 2009 Dec 5.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验